Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Instituto de investigación
Hospital de Móstoles
Móstoles, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Móstoles (13)
2024
-
Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort
Critical Care, Vol. 28, Núm. 1
-
Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine
European Journal of Clinical Investigation
2023
-
Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis
The European respiratory journal, Vol. 61, Núm. 3
-
Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients
Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215
-
Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945
2022
-
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study
Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864
-
Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units
Archivos de Bronconeumologia, Vol. 58, pp. 22-31
-
Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study
The Lancet Regional Health - Europe, Vol. 18
2016
-
Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
Critical Care, Vol. 20, Núm. 1
2014
2011
-
Impact of obesity in patients infected with 2009 influenza A(H1N1)
Chest, Vol. 139, Núm. 2, pp. 382-386
2007
-
Circulating human monocytes in the acute coronary syndrome express a characteristic proteomic profile
Journal of Proteome Research, Vol. 6, Núm. 2, pp. 876-886
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81